{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-139121","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.334047+00:00","generated_at":"2026-05-29T00:12:42.661617+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs","bullets":["CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.","Severance compensation consistent with service agreement terms (Exhibits 10.24, 10.25 to 2023 10-K).","No replacement appointed; company restructures clinical leadership without a CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-139121","json":"https://secwatch.observer/filing/0000950170-24-139121.json","markdown":"https://secwatch.observer/filing/0000950170-24-139121.md","text":"https://secwatch.observer/filing/0000950170-24-139121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024139121/0000950170-24-139121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024139121/sndx-20241220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:12:42.661617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}